Positive Results in Phase 3 Chronic Inflammatory Demyelinating Polyneuropathy Trial
According to a story from Business Wire, the pharmaceutical company Takeda recently presented results from its phase 3 clinical trial evaluating HYQVIA (Human Immune Globulin Infusion 10% with Recombinant Human…